Clinical Efficacy and Safety of Achieving Very Low LDL-Cholesterol Concentrations with The PCSK9 Inhibitor Evolocumab: A Prespecified Secondary Analysis of The FOURIER Trial
Giugliano RP, Pedersen TR, Park J-G, et al.
The Lancet. 2017;390(10106):1962-71
Leggi